Genomic Vision SA (GV.PA) Comparison with companies in other sectors?

Genomic Vision SA has a share price of 385.11M. You can analyze Genomic Vision SA (GV.PA) competitors across different market sectors through stock heatmaps.

What are GV.PA's NET and operating margins?

Genomic Vision SA (GV.PA) operating margin is around -4.14, and net profit margin is approximately -4.58 as of the latest reports.

In what way does GV.PA's earnings per share (EPS) trend reflect its financial momentum?

Genomic Vision SA (GV.PA) EPS is -0.11 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Genomic Vision SA is -0.02, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Genomic Vision SA?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Genomic Vision SA like P/E which is -0.04, P/B which is -0.19, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Genomic Vision SA

GV.PA•EURONEXT

Healthcare

Medical - Diagnostics & Research

€0.002

€0.00(5.88%)

Fundamental Analysis of Genomic Vision SA (GV.PA)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.11

P/E Ratio

-0.02

ROE

-7.61%

Net Margin

-4.58%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$693.19K

Shares OutstandingTotal number of shares issued

$385.11M

Book Value/ShareNet worth per share

$-0.01

Revenue/ShareAnnual revenue per share

$0.01

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.11

Net MarginNet income as percentage of revenue

-457.84%

Operating MarginOperating income as percentage of revenue

-413.65%

ROEReturn on shareholders' equity

-760.92%

ROAReturn on total assets

-135.82%

ROCEReturn on capital employed

-568.43%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.03

Cash/ShareCash and equivalents per share

$0.006

FCF YieldFree cash flow as percentage of market cap

-650.90%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for GV.PAFinancial Ratios Analysis details for GV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for GV.PASector Benchmarking details for GV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Genomic Vision SA Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Genomic Vision SA. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Genomic Vision SA's unique business strengths and challenges.

Key Financial Metrics for Genomic Vision SA

For Genomic Vision SA, essential financial indicators include EPS -0.11, PE -0.02, and ROE -7.61. These key ratios reveal insights into Genomic Vision SA's profitability, valuation, and operational health. Understanding these metrics enables you to compare Genomic Vision SA with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Genomic Vision SA

Metrics like Net Margin -457.84% and ROA -135.82% shed light on how well Genomic Vision SA is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Genomic Vision SA can sustain its operations and continue growing in the future.

Valuation and Market Position of Genomic Vision SA

Using ratios such as P/B Ratio -0.19 and PEG Ratio -0.00, investors can assess whether Genomic Vision SA is appropriately valued based on its financials and growth potential. These figures, combined with Genomic Vision SA's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Genomic Vision SA

Financial health indicators, such as Debt/Equity Ratio -1.89 and Cash Flow $-0.03, provide a snapshot of Genomic Vision SA's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Genomic Vision SA, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Genomic Vision SA

Investing in Genomic Vision SA based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Genomic Vision SA focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;